New Drug, Generic, and Biosimilar Pipeline Report

By constantly monitoring the pipeline, you can ensure that you are providing the most clinically effective and cost-efficient options available. Here is what you can expect from our report:


  • A list of newly approved brand-name drugs
  • Key generic and biosimilar entries
  • Administration routes, approval timelines, and cost projections
  • Applicable therapeutic areas

We publish this pipeline report quarterly to assist your pharmacy benefit management planning and strategies. To learn more, you can read about our clinical services and strategies or talk to a Sales Rep.


Download the Q2 2024 pipeline report PDF


New Drug Pipeline

GENERIC NAMEBRAND NAME
(Manufacturer if drug name unavailable)
ROUTE OF ADMINISTRATIONSTATUSESTIMATED COSTTHERAPEUTIC AREASPECIALTY
OR TRADITIONAL
Scopolamine(Repurposed Therapeutics/Defender Pharmaceuticals)Nasal*CRL Jan 2024TBDGastrointestinal: Motion SicknessTraditional
BudesonideEohiliaOral*1H2024
Launched Feb 2024
$5,250 per courseGastrointestinal: Eosinophilic EsophagitisSpecialty
Roluperidone(Mitsubishi Tanabe Minerva)OralCRL Feb 2024$20,000-$30,000
annually
Central Nervous System: SchizophreniaTraditional
AprocitentanTryvioOralApproved Mar 2024$5,000-$10,000
annually
Cardiovascular: HypertensionSpecialty
GivinostatDuvyzatOralApproved Mar 2024$350,000 annuallyCentral Nervous System: Duchenne Muscular DystrophySpecialty
VadadustatVafseoOralApproved Mar 2024TBDHematological Agents: Chronic Kidney DiseaseSpecialty
Macitentan; Tadalafil STCTOpsynviOralLaunched Mar 2024$150,000 annuallyPulmonary: Pulmonary Arterial HypertensionSpecialty
ResmetiromRezdiffraOralLaunched Mar 2024$48,000 annuallyEndocrine: Metabolic Dysfunction associated Steatohepatitis (MASH)Specialty
SotaterceptWinrevairSubcutaneousLaunched Mar 2024$250,000-
annually
Pulmonary: Pulmonary Arterial HypertensionSpecialty
Glatiramer AcetateGA DepotIntramuscular*CRL Mar 2024TBDCentral Nervous System: Multiple SclerosisSpecialty
MavorixaforXolremdiOralApproved Apr 2024$100,000-
$200,000 annually
AutoimmuneSpecialty
PivmecillinamPivyaOralApproved Apr 2024$200-$500 per courseAnti-Infectives: AntibioticsTraditional
TovorafenibOjemdaOralApproved Apr 2024$250,000 annuallyCancer: BrainSpecialty
DanicopanVoydeyaOralLaunched Apr 2024$50,000 annuallyHematologic: Paroxysmal nocturnal hemoglobinuriaSpecialty
PalopegteriparatideTransCon PTHSubcutaneousMay 2024$100,000-
$300,000 annually
Endocrine: HypoparathyroidismSpecialty
Rivoceranib(Jiangsu Hengrui Medicine
LSK BioPharma)
OralMay 2024TBDCancer: GastrointestinalSpecialty
Elafibranor(Genfit; Ipsen)OralJun 2024TBDEndocrine: Primary Biliary CholangitisSpecialty
Ensifentrine(Ligand Pharma)InhaledJun 2024$18,000 annuallyRespiratory: Asthma/COPDTraditional
Sofdra(Brickell Biotech)TopicalJun 2024$5,000-$10,000
annually
Dermatology: HyperhidrosisTraditional
Crovalimab(Roche/Chugai)Intravenous/Subc utaneousJul 2024$450,000Hematological: Paroxysmal Nocturnal HemoglobulinuriaSpecialty
Deuruxolitinib(Concert/Sun)OralJul 2024TBDDermatology: Alopecia AreataSpecialty
Galantamine Benzoate(Alpha Cognition)OralJul 2024TBDCentral Nervous System: Alzheimer’s/DementiaTraditional
NaloxoneOrexoNasal*Jul 2024TBDAddiction/Substance AbuseTraditional
DiazepamLibervantOral*Apr 2024
Aug 2024
TBDCentral Nervous System: EpilepsySpecialty
Midomafetamine (MDMA)(MAPS PBC; Lykos
Therapeutics)
Oral2H2024
Aug 2024
$5,000-$10,000
per course
Central Nervous System: Mood DisordersSpecialty
NemolizumabMitchgaSubcutaneousAug 2024TBDDermatologySpecialty
Seladelpar(CymaBay Therapeutics)Oral2H2024
Aug 2024
$110,000 annuallyGastrointestinal: Primary biliary cholangitisSpecialty
Vorasidenib(Servier Laboratories)OralAug 2024TBDCancer: GliomaSpecialty
ArimoclomolMiplyffaOralJun 2024
Sept 2024
$500,000-
$1,000,000
Endocrine: Niemann-Pick disease Type CSpecialty
Revumenib(Syndax)Oral2H2024
Sept 2024
TBDCancer: LeukemiaSpecialty
Tradipitant(Vanda Pharmaceuticals)OralSept 2024$10,000 per courseGastroenterology: NauseaSpecialty
Xanomeline; Trospium ChlorideKarXTOralSept 2024$20,000-$30,000
annually
Central Nervous System: SchizophreniaTraditional
Lebrikizumab(Eli Lilly)Subcutaneous2H2024
Oct 2024
$50,000Dermatology: Atopic DermatitisSpecialty
Acoramidis(BridgeBio/Eidos Therapeutics)Oral4Q2024
Nov 2024
$200,000 –
$300,000 annually
 
Endocrine: Metabolic
Specialty
Govorestat(Applied Therapeutics)Oral4Q2024
Nov 2024
TBD 
Endocrine: Metabolic
Specialty
Follitropin DeltaRekovelleSubcutaneous*1H2024TBD 
Endocrine: Metabolic
Specialty
RilpivirineEdurantOral2Q2024$17,700 annuallyAnti-Infectives: HIVTraditional
Insulin icodec(Novo Nordisk)Subcutaneous2Q2024
3Q2024
$5,000 annuallyEndocrine: DiabetesTraditional
Glepaglutide(Zeland Pharma)Subcutaneous4Q2024$540,000 annuallyGastrointestinal: Short Bowel SyndromeSpecialty
Lazertinib(YuHan)Oral4Q2024TBDCancer: Non- Small Cell Lung CancerSpecialty
OcrelizumabOcrevusSubcutaneous4Q2024$78,000Central Nervous System: Multiple SclerosisSpecialty
Vicagrel(Jiangsu Vcare Pharmatech)Oral4Q2024$5,000-$10,000
annually
Cardiovascular: Acute Coronary SyndromeSpecialty
*New Formulation of an Existing Product
Source: IPD Analytics, 2024

Key                                                                                                             

Launched MM YYYYMonth and year drug was launchedWithdrawnDrug has been withdrawn from FDA approval
Approved MM YYYYMonth and year drug was approvedCRLComplete Response Letter – Incomplete FDA Application
DateDate Updated release date 

Generic and Biosimilar Pipeline

DRUG NAMEBRAND NAMEROUTE OF ADMINISTRATIONSTATUSESTIMATED 2023 US SALES (MILLIONS)THERAPEUTIC AREABIOSIMILAR
OR
TRADITIONAL
Insulin GlargineLantusSubcutaneous1Q2024 Withdrawn$11,755Endocrine: DiabetesTraditional
DeflazacortEmflazaOralFeb 2024 Launched Feb 2024$249Musculoskeletal: Duchenne Muscular DystrophyBiosimilar
GabapentinGraliseOralJan 2024 Launched Feb 2024$100Central Nervous SystemTraditional
Zymfentra (Infliximab)Remicade*SubcutaneousFeb 2024 Launched Feb 2024$6,137Anti-InflammatoryBiosimilar
RisperidoneRisvanIntramuscularApproved Apr 2024$15,000- $35,000/yearCentral Nervous System: AntipsychoticTraditional
Xlucane (Ranibizumab)LucentisIntravitreal*CRL Apr 2024$1,242Ophthalmic: Macular DegenerationBiosimilar
EdaravoneRadicavaIntravenousMay 2024$330Central Nervous System: ALSBiosimilar
AfliberceptEyleaIntravitrealJun 2024$6,795Ophthalmic: Macular DegenerationBiosimilar
LiraglutideVictozaSubcutaneousJun 2024$3,678Endocrine: DiabetesTraditional
DasatinibSprycelOralSept 2024$$2,528CancerBiosimilar
OxcarbazepineOxtellar XROralSept 2024$230Central Nervous System: EpilepsyTraditional
Phentermine/Topiri mateQsymiaOralDec 2024$51Endocrine: ObesityTraditional
Toclizumab
(Tyenne)
ActemraIntravenous*2024-2025
Jan 2025
$1,048Anti-InflammatoryBiosimilar
UstekinumabStelaraSubcutaneousJan 2025$20,616Anti-InflammatoryBiosimilar
NilotinibTasignaOralJan 2024 1Q2024$1,242Cancer: LeukemiaBiosimilar
Zercepac (Trastuzumab)HerceptinIntravenous1Q2024$559Cancer: BreastBiosimilar
BrimonidineLumifyOphthalmic2H2024$41OphthalmicTraditional
DenosumabProliaSubcutaneous2024-2025$3,753CancerBiosimilar
RaltegravirIsentressOral2024$355Anti-Infectives: HIVTraditional
TeduglutideGattexSubcutaneous2024$500GastrointestinalBiosimilar
Launched MM YYYYMonth and year drug was launchedWithdrawnDrug has been withdrawn from FDA approval
Approved MM YYYYMonth and year drug was approvedCRLComplete Response Letter – Incomplete FDA Application
DateDate Updated release date 
*New Formulation of an Existing Product
Source: IPD Analytics, 2024

Nothing herein is or shall be construed as a promise or representation regarding past or future events, and Serve You Rx expressly disclaims any and all liability relating to the use or reliance on the information contained in this publication. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial, or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to, or disclosed to others at any time without the prior written consent of Serve You Rx.


Past Quarterly Pipeline Reports

Click the links below to download past quarterly reports.


About Serve You Rx   
Serve You Rx is a full-service pharmacy benefit manager (PBM) with unquestionable flexibility and an unwavering commitment to doing what’s best for its clients. With a fervent focus on those it serves, including insurance brokers, consultants, third-party administrators, and their clients, Serve You Rx delivers exceptional service and tailored, cost-effective benefit solutions. Independent and privately held for over 37 years, Serve You Rx can implement new groups in 30 days or less and say “yes” to a wide variety of viable solutions. Known for its adaptability, quality, and client-centricity, Serve You Rx aims to be a benchmark for better client service.


Want articles like this sent right to your inbox? Sign up today.